The company
Swiss clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.
The funding
NUCLIDIUM, based in Zurich, Switzerland, announced CHF 26M in Series B financing on May 29, 2026.
Participants include Aurea, Bayern Kapital, Wellington Partners, Angelini Ventures, VIVES Partners, Neva SGR, Kurma Growth Opportunities Fund, NRW.Bank.